As of November 27, CRISPR Therapeutics AG (NASDAQ:CRSP) has a moderately positive opinion, with 60% analysts covering it having a Buy or equivalent rating. With a consensus 1-year median price target ...

But sometimes, this top investor who focuses on innovation does see eye-to-eye with analysts, and the perfect example of this ...

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best short squeeze stocks to buy right now. Citizens reaffirmed its ...

To compile our list of the best short squeeze stocks, we made use of stocks screeners to note down stocks with significant ...

Fintel reports that on November 26, 2025, Chardan Capital maintained coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

Thinking about whether CRISPR Therapeutics stock is truly a bargain or just the next biotech craze? Let’s break down its value case together. After a sharp rally earlier this year, the stock is still ...

Agios Pharmaceuticals, Inc. drops after mixed Phase 3 mitapivat results in Sickle Cell Disease. Click here to find out why ...

Week 11 of the 2025 NFL season kicked off on Thursday with a surprise of sorts with the New York Jets (2-8) keeping pace early with the New England Patriots (9-2) in a ...

First place in the NFC West, and the top seed in the NFC will be on the line. Plus, the Broncos will need Bo Nix to step up in a big matchup with the Chiefs. Seahawks quarterback Sam Darnold faces his ...

Semiconductor industry giant Applied Materials Inc. beat expectations for its latest financial results and forecast higher sales in the coming year thanks to artificial intelligence demand, but its ...

Fintel reports that on November 12, 2025, Citigroup maintained coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a Buy recommendation. Analyst Price Forecast Suggests 57.77% Upside As of November 8 ...